Skip to content
Tallac Therapeutics, Inc
Tallac Therapeutics, Inc

News

Home
News
2022
July
  • 28 Jul, 2022

Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors

view more
Tallac Therapeutics, Inc
  • (650) 866-1966
866 Malcolm Road Suite 100, Burlingame, CA 94010
Linkedin-in Envelope

Copyright © 2020-2025 Tallac Therapeutics, Inc. All Rights Reserved.